December 9, 2015

Cerberus Capital management invests $105M in PaxVax

Source: FiercePharma
Publication Date: December 9, 2015
Visit Source

Redwood City, CA-based PaxVax currently markets one vaccine, Vivotif, the typhoid vaccine it acquired from Johnson & Johnson’s ($JNJ) Crucell in July 2014. But PaxVax could be on the way to adding its cholera candidate, Vaxchora, to the list thanks to a $105 million investment from Cerberus Capital management.